Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
QuintilesIMS
Cantor Fitzgerald
AstraZeneca
Queensland Health
UBS
US Army
Harvard Business School
Dow

Generated: January 19, 2018

DrugPatentWatch Database Preview

KEPPRA Drug Profile

« Back to Dashboard

Which patents cover Keppra, and when can generic versions of Keppra launch?

Keppra is a drug marketed by Ucb Inc and is included in four NDAs. There are two patents protecting this drug and three Paragraph IV challenges.

The generic ingredient in KEPPRA is levetiracetam. There are thirty-five drug master file entries for this compound. Ninety-nine suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.

US Patents and Regulatory Information for KEPPRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc KEPPRA levetiracetam INJECTABLE;IV (INFUSION) 021872-001 Jul 31, 2006 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ucb Inc KEPPRA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 022285-001 Sep 12, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-001 Nov 30, 1999 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Ucb Inc KEPPRA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 022285-002 Feb 12, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Ucb Inc KEPPRA levetiracetam SOLUTION;ORAL 021505-001 Jul 15, 2003 AA RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-004 Jan 6, 2006 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-003 Nov 30, 1999 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-002 Nov 30, 1999 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for KEPPRA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-001 Nov 30, 1999 ➤ Subscribe ➤ Subscribe
Ucb Inc KEPPRA levetiracetam INJECTABLE;IV (INFUSION) 021872-001 Jul 31, 2006 ➤ Subscribe ➤ Subscribe
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-002 Nov 30, 1999 ➤ Subscribe ➤ Subscribe
Ucb Inc KEPPRA levetiracetam SOLUTION;ORAL 021505-001 Jul 15, 2003 ➤ Subscribe ➤ Subscribe
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-001 Nov 30, 1999 ➤ Subscribe ➤ Subscribe
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-004 Jan 6, 2006 ➤ Subscribe ➤ Subscribe
Ucb Inc KEPPRA levetiracetam SOLUTION;ORAL 021505-001 Jul 15, 2003 ➤ Subscribe ➤ Subscribe
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-003 Nov 30, 1999 ➤ Subscribe ➤ Subscribe
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-002 Nov 30, 1999 ➤ Subscribe ➤ Subscribe
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-003 Nov 30, 1999 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for KEPPRA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablet 500 mg and 750 mg ➤ Subscribe 1/7/2011
➤ Subscribe Tablets 1000 mg ➤ Subscribe 1/24/2007
➤ Subscribe Extended-release Tablets 1000 mg ➤ Subscribe 1/7/2011

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Accenture
AstraZeneca
QuintilesIMS
McKesson
Julphar
Cantor Fitzgerald
Teva
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot